TB006 represents a distinct path in the ongoing effort to address Alzheimer’s disease and related dementias. Unlike many existing treatments that primarily slow progression, this investigational therapy targets Galectin-3 (Gal-3), a protein linked to neuroinflammation and the formation of harmful protein aggregates in the brain.

By neutralizing Gal-3, TB006 aims to interrupt processes that contribute to amyloid plaque buildup and chronic inflammation. Early clinical observations and patient experiences under the Expanded Access Program have shown signals of cognitive stabilization or improvement in some individuals, along with a favorable tolerability profile. Results vary, and TB006 remains investigational—it is not FDA-approved and is not a cure.

Treatment is administered as a monthly intravenous infusion, typically lasting about one hour. It is currently available to eligible patients through the FDA’s Expanded Access (compassionate use) pathway for those with Alzheimer’s disease or other forms of dementia who meet specific criteria.

If you or a loved one is navigating the challenges of cognitive decline, learning more about emerging options can be an important next step. Our team is here to provide clear information, discuss eligibility for the Expanded Access Program, and help you understand whether TB006 may be appropriate to explore. Most people see significant results in only 5 sessions.

Contact us today to schedule a consultation or request additional details. We’re ready to answer your questions and support you in taking the next informed step.